Investigational Drug Details
| Drug ID: | D237 |
| Drug Name: | Trifluoperazine |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB00831 |
| DrugBank Description: | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. |
| PubChem ID: | 5566 |
| CasNo: | 117-89-5 |
| Repositioning for NAFLD: | Yes |
| SMILES: | CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1 |
| Structure: |
|
| InChiKey: | ZEWQUBUPAILYHI-UHFFFAOYSA-N |
| Molecular Weight: | 407.496 |
| DrugBank Targets: | Dopamine D2 receptor; Neuron-specific vesicular protein calcyon; Alpha-1A adrenergic receptor; Calmodulin; Troponin C, slow skeletal and cardiac muscles; Protein S100-A4 |
| DrugBank MoA: | Trifluoperazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis. |
| DrugBank Pharmacology: | Trifluoperazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Trifluoperazine has not been shown effective in the management of behaviorial complications in patients with mental retardation. |
| DrugBank Indication: | For the treatment of anxiety disorders, depressive symptoms secondary to anxiety and agitation. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|